Wei et al recently reported that inhibition of PP2A sensitizes human pancreatic cancer cell lines in vitro and in vivo by inhibition of homologous recombination repair of DNA and activation of Cdc25c/Cdk1 signaling, suggesting that inhibition of PP2A is a potential target for enhancing local therapy in pancreatic cancer [56]. Here, CDK1 is linked to pancreatic neoplasm.